Stephen Saad’s stake in Africa’s largest pharmaceutical company sinks below $600 million
South African pharmaceutical tycoon Stephen Saad faces setback as Aspen Pharmacare shares decline.
Related
Stephen Saad’s Aspen faces $148.7 million contract dispute
Aspen shares dive 30% amid $148.7 million mRNA tech dispute, stoking investor fears over financial stability.
Stephen Saad’s stake in Aspen slips below $450 million
South African pharma tycoon Stephen Saad’s stake in Aspen Pharmacare drops to $434.35 million, losing $62.85 million in 15 days.
Stephen Saad’s wealth takes a hit as Aspen Pharmacare stock plunges, erasing $41 million
This downturn follows a $44 million gain in January, which had lifted his stake to R10.26 billion ($550.1 million).
Stephen Saad leads Africa’s largest drugmaker to $1.2 billion in half-year revenue
The growth was fueled by the successful integration of acquired products in Latin America.
Latest
Edha Nahdi's Bamburi Cement launches concrete plant in Mombasa
Bamburi Cement, now owned by Edha Nahdi’s Amsons Group, has launched a new concrete plant in Mombasa to meet rising demand and fuel its recovery.
Patrice Motsepe’s firm barred from phosphate asset
Conservationists have fought against the project from the start, warning it could cause lasting damage to one of South Africa’s most sensitive ecosystems.
Johann Rupert’s Richemont finalizes YNAP divestment to Mytheresa
Richemont finalizes $609.7 million YNAP divestment to Mytheresa, marking a major shift in luxury e-commerce and boosting Mytheresa’s global market position.
Vukile, led by Laurence Rapp, completes $7.5 million Bedworth Center upgrade
The upgrade is part of Vukile’s ongoing effort to invest with real purpose, shaping spaces that are built around the people who use them every day.